equicenta® CTM
equicenta® CTM is part of a broader commitment to raise the bar for equine biologics.
Our peer-reviewed trial in Frontiers in Veterinary Science is live, the largest controlled trial of its kind in equine regenerative medicine.
equicenta® CTM
equicenta® CTM is a cryopreserved equine umbilical-cord-tissue allograft. Supplied as a single, ready-to-use dose, it eliminates the need for an autologous blood draw, chairside processing, or corticosteroid administration.
Unlike an acellular fluid, such as plasma, that disperses following injection, equicenta® CTM retains a native fetal extracellular-matrix scaffold at the treatment site. This scaffold contains a characterized multimodal structural proteins, growth factors, cytokines, and extracellular vesicles. The retained matrix is designed to provide structural support and progressively release its biological components over time, supporting a local environment associated with the body’s natural tissue-repair processes.
Request Scientific Info
BMC Medicine, 2025
In published characterization (Bertone et al., BMC Medicine, 2025), equicenta® CTM was found to contain:
The paper also reports a controlled biocompatibility study in 8 clinically normal horses over 42 days. This controlled biocompatibility study does not establish efficacy. equicenta® CTM is investigational; absolute safety has not been established.
Frontiers in Veterinary Science, 2026
In a published, open-label controlled trial (Bertone et al., 2026), equicenta® CTM was compared with clinician-selected, non-steroidal standard-of-care biologics in 138 horses with 195 conditions at 8 U.S. specialty equine practices, with a 26-week performance endpoint. Injection reactions were reported after 3.4% of equicenta® CTM injections and 10.5% of standard-of-care injections.
Frontiers in Veterinary Science · 2026
Source: Bertone AL, et al. Front. Vet. Sci. 2026.
Exclusive Sourcing
We partner directly with our source — a premier Louisiana breeder of registered racehorses. Our teams work closely to ensure our product is derived from full-term, natural deliveries within a single-source herd, maintaining the highest standards for mare and foal welfare.
Coteau Grove Farms: Founded in 2008 by Keith and Ginger Myers, Coteau Grove Farms delivers exceptional, personalized care while breeding top-tier Louisiana-bred racehorses that compete—and win—nationwide. With champions like No Parole and Touchupsmaster, and a steady infusion of elite bloodlines, the farm continues to produce winners year after year.
Learn More
Day 0 Grade 3 RF lameness, blocked to foot — tracking response over time.
Read More
Severe LF lameness with prior ligament intervention — complex case, structured response.
Read More
The structural protein behind every tendon, ligament, and joint — explained simply.
Read MoreInterested in what Equine Performance Labs is up to?
Now Published
In a published, open-label controlled trial (Bertone et al., 2026), a single injection of equicenta® CTM was associated with 2.72:1 odds of returning to prior performance. Injection reactions were reported after 3.4% of equicenta® CTM injections and 10.5% of standard-of-care injections.
Study limitations: open-label design; heterogeneous, clinician-selected comparator; funded by Equine Performance Labs.
For use by or on the order of a licensed veterinarian. Not for use in humans.
By submitting, you agree to receive occasional science and product updates from Equine Performance Labs. Unsubscribe anytime.
